Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioTime drug enters trial in Japan
Summit is co-developing Hextend for the Japanese market with Maruishi Pharmaceutical and both Maruishi and Summit have the right to co-market Hextend if regulatory approval is obtained. Summit
Summit is co-developing Hextend for the Japanese market with Maruishi Pharmaceutical and both Maruishi and Summit have the right to co-market Hextend if regulatory approval is obtained. Summit
The development of Sparlon for attention deficit disorder has ceased but the FDA might delay its labeling decision concerning Nuvigil as it is a single-isomer formulation of modafinil,
The studies, which were performed in collaboration with the Karolinska Institute in Sweden, suggest that AV-101 may have therapeutic potential for treating the symptoms of Parkinson’s disease and
Iloperidone demonstrated statistically significant improvement compared to placebo on the Positive and Negative Symptom Scale (PANSS), the trial’s primary endpoint. Additionally, iloperidone achieved significant efficacy on the positive
Evista is currently indicated for the treatment and prevention of osteoporosis in postmenopausal women. Evista prevents and treats osteoporosis by helping make bones stronger and less likely to
Xenon and Roche have entered into a worldwide research and license agreement to jointly research protein-based inhibitors of hemojuvelin (HJV). In addition to the research and license agreement
The research offers evidence of a potential drug target in a flu protein called nucleoprotein, or NP. The nucleoprotein is found in strains of the virus that cause
The company is conducting an investigation to determine the root cause of this failure and believes that it is likely related to the higher than expected moisture content
Researchers said the study was the largest to evaluate Gleevec in chronic myeloid leukemia (CML). The five-year overall survival of CML patients who received Gleevec as initial therapy
The drug is being developed in partnership with Schering-Plough. The company said it expected trials to resume by mid-January and believes that the delay will not affect the